Following this. I have the same question and no better information than the first post.
8 likes 19mo
Compounds · Other compounds · continued
When "no data" is the complete and final answer posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
t.brandt, post #49: Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists. Go to post
Post #58 and I disagree about the size of the effect, not about the direction.
Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
Collapsed as off-topic by two members at trust level 3 or above
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That is what I would do. It may not be what is correct.
Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.
0 likes 18mo
Post #62 put the caveat in the right place and I want to underline it.
Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.
26 likes 18mo
a.krastev, post #60: Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Go to post
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Not a conclusion. A place to stand while looking for one.
The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose.
If anyone has run this properly I would rather read that than my own guess.
2 likes 18mo
Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.
A modest claim, modestly supported.
0 likes 18mo
Where I part company with post #69, and it is a narrow parting.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
I am describing what is, rather than arguing for what should be.
17 likes 18mo
Post #69 is the version of this I will quote in future. One addition.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
This is where my knowledge stops and I would rather mark the edge than blur it.
7 likes 18mo
s.grahame, post #72: Post #69 is the version of this I will quote in future. One addition. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. This is where my knowledge stops and I would rather mark the edge than blur it. Go to post
Fragment compounds — where the material is part of a larger natural protein — should be identified by sequence rather than by name, because the naming in this space is inconsistent between suppliers.
Anyone with a larger sample, please post it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I have seen it go both ways, which is why I hedge.
0 likes 18mo
Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness.
The short answer was in the first line; everything after is the working.
24 likes 18mo
Building on post #73 rather than restating it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The right answer here may simply be that it has not been measured.
11 likes 18mo
nl_translator, post #68: The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose. If anyone has run this properly I would rather read that than my own guess. Go to post
PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.
plateau_notes, post #51: Noted, and I have changed what I was going to do on the strength of it. Go to post
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
m.malinowski, post #34: Adding the measurement that post #33 says would settle it. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. That has been true for the cases I have seen and I have not seen many. Go to post
That is the distinction I keep failing to hold on to. Written down now.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I would put the burden of proof on the interesting explanation, not the dull one.
17 likes 18mo
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Marking that as an opinion rather than a finding.
32 likes 18mo
o.abrahamsen, post #11: The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence. That is the shape of it. The detail is where I would expect to be corrected. Go to post
Post #82 answers the question as asked. The question underneath it is different.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
y.ramos, post #30: Coming back to post #26, because the follow-up matters more than the original answer. Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile. Adding the caveat now so it does not have to be… Go to post
I read post #81 twice before replying, because I had assumed the opposite.
Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.
Narrowing post #85, because the general version has more than one answer.
AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.
0 likes 18mo
s.karlsen_rph, post #40: Taking post #37 at face value and following it one step further. Storage guidance for the less common material is usually copied from the incretin guidance and may not apply. Where the supplier has its own stability statement, that is the one to use. Anyone who has looked at this more carefully, please correct the record. Go to post
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The reasoning is more useful than the number, which is why I have shown it.
Adding the measurement that post #87 says would settle it.
This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.
7 likes 18mo
a.kowalczyk, post #53: Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Go to post
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.